Eisai | pharmaphorum

Friday 5 December 2025

Eisai

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

News

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

Eisai plans ‘patient-proposed’ trial of cancer drug Tazverik

Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treat

News

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

Department of Veterans Affairs will cover the drug for veterans with early-stage Alzheimer's.

News

FDA sets July verdict date for Leqembi, after adcomm meeting

FDA sets July verdict date for Leqembi, after adcomm meeting

After priority review, regulator will consider upgrading the drug's status to full approval.

News

drug pricing

Leqembi still too pricey, says ICER in updated review

Side effects create 'uncertainties' as to whether lecanemab's benefits exceed its risks.

News

CMS accused of discrimination over Alzheimer’s drug verdict

CMS accused of discrimination over Alzheimer’s drug verdict

Decision not to revisit coverage decision for amyloid drugs is slammed by patient groups.